title: [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
authors.affiliation: Institutionen för kliniska vetenskaper, avdelningen för onkologi, Lunds universitet.
authors.forename: Mårten
authors.initials: M
authors.lastname: Fernö
authors.forename: Monica
authors.initials: M
authors.lastname: Haglund
authors.forename: Pär-Ola
authors.initials: PO
authors.lastname: Bendahl
authors.forename: Hans
authors.initials: H
authors.lastname: Olsson
authors.forename: Lisa
authors.initials: L
authors.lastname: Rydén
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D017404:In Situ Hybridization, Fluorescence / Q000592:standards; D011237:Predictive Value of Tests; D011379:Prognosis; D011785:Quality Assurance, Health Care; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000378:metabolism; D015203:Reproducibility of Results; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab